Live Feeds
● LIVE Updated 1h ago · 19 sources tracked

It now seems possible to vaccinate against cancer

A positive trial for a Moderna cancer vaccine provides hope for treating patients, though researchers emphasize that more work is required to move these effective vaccines into clinical settings. This follows previous findings that a personalized mRNA vaccine, used alongside Keytruda, prevents melanoma from spreading or returning in high-risk patients after surgery. While these results show potential for long-term cancer-free survival, the current focus is on accelerating the development of personalized therapies to make them widely available to the public.

RSS Source map (19)

What changed

Nature reports that while trial results are promising, further research is necessary to transition these personalized therapies into clinical use.

Live updates

  1. Moderna cancer vaccine trials prompt calls for faster personalized therapy

    A positive trial for a Moderna cancer vaccine provides hope for treating patients, though researchers emphasize that more work is required to move these effective vaccines into clinical settings. This follows previous findings that a personalized mRNA vaccine, used alongside Keytruda, prevents melanoma from spreading or returning in high-risk patients after surgery. While these results show potential for long-term cancer-free survival, the current focus is on accelerating the development of personalized therapies to make them widely available to the public.

    Why it matters

    The development of these mRNA vaccines follows a decade of logistical and pandemic-related challenges. This technology aims to remodel the immune system to generate T cells that can eradicate or slow tumor growth.

    What is confirmed

    • A personalized mRNA vaccine developed by Moderna and Merck prevents melanoma from returning or spreading in high-risk patients when paired with Keytruda.
    • Positive trials for the Moderna cancer vaccine show promise for treating people with cancer.

    What to watch next

    • Clinical trial results for personalized mRNA therapies beyond melanoma
    • Regulatory approval timelines for the Moderna and Merck vaccine combination
    Sources used for this update (9)
    1. inews.co.uk — Hegseth’s escalating purge is rocking the US military
    2. inews.co.uk — CIA chief’s secret trip to Moscow shows Putin’s threat to Nato is deadly serious
    3. www.yahoo.com — Why we just can’t shake our obsession with curses
    4. inews.co.uk — Putin is up to something – it will be dirty and deniable
    5. inews.co.uk — Young people with anxiety and ADHD to be offered taxpayer-funded jobs at Boots
    6. www.yahoo.com — Rescue Kitten Clings to Dog Like She’s Her Mama & It’s Exactly What They Both Need
    7. inews.co.uk — The surprise bonus benefits of four common vaccines
    8. apnews.com — Live updates: Death toll rises in Nepal-China border disaster as lake poses new flood threat
    9. www.nature.com — The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
    confidence 90%

  2. Moderna and Merck vaccine reduces melanoma recurrence risk

    An experimental personalized mRNA vaccine developed by Moderna and Merck prevents melanoma from returning or spreading in high-risk patients. When paired with the drug Keytruda, the treatment helps patients stay cancer-free longer following surgery. This result follows a decade of development characterized by logistical hurdles and pandemic-era obstacles. Separate research into mRNA molecules also shows potential for remodeling the immune system to generate T cells capable of slowing or eradicating tumor growth.

    Why it matters

    Melanoma is a high-risk skin cancer prone to recurrence after surgical removal. Personalized vaccines tailor treatment to the individual's specific cancer markers to trigger a targeted immune response. This shift toward mRNA-based oncology represents a move from general chemotherapy toward precision medicine.

    What is confirmed

    • Moderna and Merck developed an experimental vaccine that prevents melanoma from returning or spreading in high-risk individuals.
    • A personalized mRNA vaccine used alongside Keytruda may prevent skin cancer recurrence after surgery.

    Still unconfirmed

    • Researchers generated T cells using mRNA molecules that can slow tumor growth or eradicate tumors.

    What to watch next

    • Peer review of the large clinical trial data
    • Regulatory approval filings for the personalized vaccine
    • Results from expanded trials targeting other cancer types
    Sources used for this update (8)
    1. medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
    2. www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
    3. en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
    4. www.sciencenews.org — A new cancer vaccine may keep melanoma from coming back
    5. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
    6. www.yahoo.com — Baby Girl Names From The '70s That Are Making A Comeback
    7. www.technologyreview.com — Amping up T cells to target cancer
    8. www.yahoo.com — Please stop putting AI-generated food on the menu
    confidence 90%

  3. Cancer vaccination shows promise with Moderna's melanoma vaccine

    Moderna's melanoma vaccine, developed with Merck, has shown promising results in a large trial, potentially paving the way for cancer vaccination. The vaccine, designed to prevent skin cancer recurrence, has sparked optimism about its effectiveness. This development could lead to a new approach in cancer treatment.

    Why it matters

    The fight against cancer has seen significant advancements, with vaccination emerging as a potential strategy. Moderna's success with its COVID-19 vaccine has translated to cancer research, with the company's melanoma vaccine demonstrating encouraging results. The vaccine's ability to prevent cancer recurrence could revolutionize treatment options.

    What is confirmed

    • Moderna shares surged after announcing the success of their melanoma vaccine in a large trial.
    • The melanoma vaccine was developed in partnership with Merck.
    • The vaccine aims to prevent skin cancer from recurring in patients.

    Still unconfirmed

    • Investors thought Moderna was left for dead before the cancer breakthrough.

    What to watch next

    • Further trial results for Moderna's melanoma vaccine
    • FDA approval process for the vaccine
    • Potential applications of the vaccine in other types of cancer
    Sources used for this update (9)
    1. baynews9.com — New study shows personalized vaccine may help prevent skin cancer from recurring in patients
    2. Reuters — Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
    3. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
    4. CNN — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    5. The Washington Post — Opinion | A cancer vaccine would be a miracle of science — and the free market
    6. The Economist — It now seems possible to vaccinate against cancer
    7. WSJ — Investors Thought Moderna Was Left for Dead. Then Came a Cancer Breakthrough.
    8. WCAX — New melanoma vaccine could shed light on Vermont’s high rates
    9. Bloomberg.com — Why Moderna’s Cancer Vaccine Is a Breakthrough for mRNA
    confidence 85%